These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15365766)

  • 1. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
    Fukuda M; Oka M; Soda H; Kinoshita A; Fukuda M; Nagashima S; Kuba M; Takatani H; Tsurutani J; Nakamura Y; Kasai T; Inoue Y; Soejima Y; Kohno S;
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):573-7. PubMed ID: 15365766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
    Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
    J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.
    Kim HS; Kim JH; Kim B; Choi HC; Kwon JH; Choi DR
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1591-7. PubMed ID: 23568282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.
    Miller AA; Case D; Atkins JN; Giguere JK; Bearden JD
    J Thorac Oncol; 2006 Oct; 1(8):832-6. PubMed ID: 17409967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers.
    Fukuda M; Oka M; Soda H; Terashi K; Kawabata S; Nakatomi K; Takatani H; Tsurutani J; Tsukamoto K; Noguchi Y; Fukuda M; Kinoshita A; Kohno S
    Clin Cancer Res; 1999 Dec; 5(12):3963-9. PubMed ID: 10632326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
    Sato M; Ando M; Minami H; Ando Y; Ando M; Yamamoto M; Sakai S; Watanabe A; Ikeda T; Sekido Y; Saka H; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):481-7. PubMed ID: 11800029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
    Ishimoto O; Sugawara S; Inoue A; Maemondo M; Nukiwa T
    Respir Investig; 2015 Jul; 53(4):156-60. PubMed ID: 26100175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
    Pillot GA; Read WL; Hennenfent KL; Marsh S; Gao F; Viswanathan A; Cummings K; McLeod HL; Govindan R
    J Thorac Oncol; 2006 Nov; 1(9):972-8. PubMed ID: 17409981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
    Pectasides D; Visvikis A; Kouloubinis A; Glotsos J; Bountouroglou N; Karvounis N; Ziras N; Athanassiou A
    Eur J Cancer; 2002 Jun; 38(9):1194-200. PubMed ID: 12044505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
    Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
    Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
    Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K
    Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.
    Pectasides D; Fountzilas G; Rigopoulos A; Bountouroglou NG; Koutras A; Glotsos J; Onyenadum A; Makatsoris T; Kalofonos HP
    Anticancer Res; 2002; 22(6B):3501-6. PubMed ID: 12552946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer.
    Takeda K; Takifuji N; Uejima H; Yoshimura N; Terakawa K; Negoro S
    Lung Cancer; 2002 Dec; 38(3):303-8. PubMed ID: 12445753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
    Natale RB; Socinski M; Sandler A; Israel VP; Miller L
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):29-34. PubMed ID: 10981288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
    Hirose T; Horichi N; Ohmori T; Ogura K; Hosaka T; Ando K; Ishida H; Noguchi H; Adachi M
    Lung Cancer; 2003 Jun; 40(3):333-8. PubMed ID: 12781433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer.
    Takeda K; Negoro S; Takifuji N; Nitta T; Yoshimura N; Terakawa K; Fukuoka M
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):104-8. PubMed ID: 11561775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
    Sohn JH; Choi HJ; Chang J; Kim SK; Lee CG; Chung KY; Kim DJ; Cho BC; Shin SJ; Moon YW; Kim JH
    Lung Cancer; 2006 Dec; 54(3):365-70. PubMed ID: 17011068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.